- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07706439
Large-Scale Evaluation of a Clinical Decision Tree for the Management of Low-Energy Thoracic and Lumbar Vertebral Compression Fractures. (PALMTREE)
Panoramica dello studio
Stato
Descrizione dettagliata
Percutaneous vertebroplasty was first described in France in 1987 . Since its introduction, this minimally invasive technique has become widely accepted and is now a routine treatment for low-energy vertebral compression fractures (LEVCFs), also referred to as vertebral "crush" fractures. Clinical outcomes, including pain relief, analgesic consumption, and quality of life assessed through self-administered questionnaires, are commonly used to evaluate the effectiveness of the procedure.
Over the past 20 years, several randomized controlled trials (RCTs) have been conducted to assess the efficacy of vertebroplasty compared with non-surgical management (including bracing and placebo treatment). Two recent meta-analyses identified 13 RCTs published by January 2019 and 14 RCTs by July 2020, reaching different conclusions.
In 2019, Lou et al. concluded that percutaneous vertebroplasty was effective and safe only in patients with acute low-energy vertebral compression fractures associated with persistent and severe pain. In contrast, Lainez Ramos-Bossini et al. concluded in 2020 that vertebroplasty offered significant benefits compared with non-surgical treatment, including short-term pain relief and improved quality of life. However, these benefits appeared more limited when vertebroplasty was compared with placebo treatment.
The conclusion of the Cochrane review published by Buchbinder et al. in 2018 remains relevant today: "Based on high- to moderate-quality evidence, our updated review does not support a role for vertebroplasty in the routine management of acute or subacute osteoporotic vertebral fractures." .
Furthermore, recent studies involving large patient cohorts have reported a significant rate of complications associated with percutaneous vertebroplasty. Among 1,932 patients, 166 (8.6%) experienced a complication, including 53 minor complications (2.7%) and 95 major complications (4.9%) . Patient selection appears to play a crucial role in the occurrence of complications, as suggested by Scheyerer et al. in a recent literature review .
The authors identified both non-modifiable and modifiable risk factors for perioperative and postoperative complications, including: age >90 years, male sex, low level of daily activity, partial or complete dependency, hospitalization, high American Society of Anesthesiologists (ASA) classification, Parkinson's disease, chronic obstructive pulmonary disease (COPD), arterial hypertension, renal failure, liver failure, coagulopathies, chronic steroid use, preoperative sepsis, and hypoalbuminemia (<3.5 g/dL) .
Simple preoperative markers, such as serum albumin levels, should therefore be considered when deciding whether vertebroplasty is appropriate for the treatment of low-energy vertebral compression fractures.
To improve the clarity and standardization of the management of patients presenting with low-energy vertebral compression fractures ("crush" fractures), we developed a clinical decision tree based on patient age, MRI findings, pain severity assessed using a Visual Analog Scale (VAS), and the extent of radiological deformity.
THE AIME OF THE STUDY IS : To evaluate the clinical and radiological healing outcomes of patients managed according to a clinical decision tree for one or more low-energy vertebral compression fractures (LEVCFs) at Grenoble Alpes University Hospital between January 1, 2022, and March 31, 2025.
Design of the study :Single-center prospective observational cohort study with no control group.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Mehdi BOUDISSA, Pr
- Numero di telefono: 0476763275
- Email: mboudissa@chu-grenoble.fr
Backup dei contatti dello studio
- Nome: Sarah KASSAR-UNEISI, Pharm D
- Numero di telefono: 0476767524
- Email: suneisi@chu-grenoble.fr
Luoghi di studio
-
-
-
La Tronche, Francia, 38700
- GRENOBLE ALPES UNIVERSITY HOSPITAL
-
Investigatore principale:
- Mehdi BOUDISSA, Pr
-
Contatto:
- Sarah PI KASSAR-UNEISI, Pharm D
- Numero di telefono: 0476767524
- Email: suneisi@chu-grenoble.fr
-
Contatto:
- Mehdi PI BOUDISSA, Pr
- Numero di telefono: 0476763275
- Email: mboudissa@chu-grenoble.fr
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Age > 50 years
- One or more low-energy vertebral compression fractures (LEVCFs) confirmed by MRI
- Fractures located between T7 and L5
- Compression fractures classified as A1.1, A1.2, or A1.3 according to the Magerl classification [15]
- Management in accordance with the clinical decision tree
- Vertebroplasty performed by an interventional radiologist, orthopedic surgeon, or neurosurgeon
- Vertebral augmentation performed by an orthopedic surgeon or neurosurgeon, with or without navigation assistance
- Conservative treatment consisting of a lumbar brace worn during daytime, with duration individualized according to the patient's needs, and physiotherapy initiated between 45 and 90 days after treatment, including core stabilization, stretching, and strengthening of the posterior muscle chain and abdominal muscles, based on active rehabilitation rather than manual therapy (no massage therapy).
Exclusion Criteria:
- Pregnant or breastfeeding women
- Individuals under administrative or judicial supervision
- Age < 50 years or > 90 years
- Pathological vertebral fracture
- Presence of other osteoporotic fractures during the study follow-up period (6 months)
- Non-compliance with the clinical decision tree
- Dementia or cognitive impairment preventing data collection at the final follow-up (telephone interview), assessed using the Mini-Cog test (score < 3 = exclusion)
- Refusal to participate during the telephone interview or inability to provide non-opposition (e.g., under legal guardianship)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Evaluate the clinical and radiological healing outcomes of patients managed according to a clinical decision tree for one or more low-energy vertebral compression fractures (LEVCFs)
Lasso di tempo: 1 year
|
Radiological fracture healing, assessed on standard radiographs based on cortical continuity, disappearance of fracture lines, absence of progressive kyphosis, and absence of osteosynthesis hardware-related complications.
Fracture healing will be classified as complete, partial, or absent.
|
1 year
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Assessment of radiological deformity.
Lasso di tempo: 1 year
|
Assessment of radiological deformity (vertebral kyphosis [VK], regional kyphosis [RK], and spinal canal narrowing) in patients managed according to the clinical decision tree
|
1 year
|
|
Assessment of clinical outcomes
Lasso di tempo: 1 year
|
EVA -pain score
|
1 year
|
|
Assessment of clinical outcomes
Lasso di tempo: 1 year
|
quality of life EQ5D 3 L
|
1 year
|
|
Assessment of clinical outcomes
Lasso di tempo: 1 year
|
Mobility -Parker Mobility Score
|
1 year
|
|
Assessment of clinical outcomes
Lasso di tempo: 1 year
|
Analysis of risk factors for failure of conservative treatment
|
1 year
|
|
Assessment of vertebroplasty cement filling quality
Lasso di tempo: 1 year
|
(Garnier classification)
|
1 year
|
|
Assessment of fracture healing and associated factors
Lasso di tempo: 1 year
|
Evaluation of time to fracture healing, comparing conservative versus surgical treatment (measured in days; for surgical treatment, time is calculated from the date of surgery)
|
1 year
|
|
Assessment of fracture healing and associated factors
Lasso di tempo: 1 year
|
Assessment of the effect of calcium and vitamin D supplementation on fracture healing and the rate of refracture or new fractures.
|
1 year
|
|
Assessment of fracture healing and associated factors
Lasso di tempo: 1 year
|
Assessment of the effect of osteoporosis treatment on fracture healing and the rate of refracture or new fractures.
|
1 year
|
|
Assessment of complications
Lasso di tempo: 1 year
|
Perioperative and postoperative complications, including cement leakage, secondary lumbar spinal canal stenosis, intravertebral cleft (Kümmell disease), adjacent vertebral fractures, and pseudarthrosis (nonunion).
|
1 year
|
|
Assessment of treatment timelines
Lasso di tempo: 1 year
|
ime intervals (in days) between fracture occurrence and MRI, between MRI and surgical consultation, and between fracture occurrence and definitive treatment.
|
1 year
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- 38RC26.0185
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .